Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines

Fig. 1

Workflow for phosphoprotein, gene expression and phenotypic analysis. MKN1 and Hs746T cells were treated with EGF, cetuximab or the combination of both. MKN1 cells are cetuximab responder and Hs746T cells are cetuximab non-responder [35, 41]. MKN1, MKN7, NCI-N87 and Hs746T cells were treated with trastuzumab, afatinib or the combination of both. NCI-N87 cells are trastuzumab responder and MKN7 and MKN1 are trastuzumab non-responder [21, 42]. NCI-N87, MKN1 and MKN7 cells are afatinib responder and Hs746T cells are afatinib non-responder [21]. Phosphoprotein analysis of selected downstream kinases, RNA sequencing, apoptosis and motility analysis were performed to compare the molecular effects of cetuximab, trastuzumab and afatinib and to identify genes involved in the phenotypic effects of the treatments

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us